Local catheter-based delivery of antithrombotic or antiproliferative drugs: A new concept for prevention of restenosis

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 236-243

  Herdeg, Christian ^a   Goehring Frischholz, Katrin ^a   Zuern, Christine ^a   Geisler, Tobias ^a   Hartmann, Ulrike ^a   Hoevelborn, Tobias ^a   Haase, Karl K ^b   Gawaz, Meinrad ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Klinikum am Steinenberg   (Germany)

Author keywords

Angioplasty; Glycoprotein VI; Local delivery; Paclitaxel

Indexed keywords

GLYCOPROTEIN VI; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; EXPERIMENTAL PIG; EXPERIMENTAL RABBIT; HUMAN; HUMAN CELL; INTIMA; INTRACORONARY INFUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RESTENOSIS; THROMBOGENESIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATHETERIZATION; CELL PROLIFERATION; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG DELIVERY SYSTEMS; FIBRINOLYTIC AGENTS; PACLITAXEL; PLATELET MEMBRANE GLYCOPROTEINS; SOLUBILITY; SWINE; TIME FACTORS; TUNICA INTIMA;

EID: 55549146800     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.02.015     Document Type: Article

References (33)

1. Teirstein P.S. Living the dream of no restenosis. Circulation 104 (2001) 1996-1998
2. Lincoff A.M., and Topol E.J. Interventional catheterization techniques. In: Braunwald E. (Ed). Heart disease. A textbook of cardiovascular medicine. Fifth edition (1997), W. B. Saunders, Philadelphia 1366-1391
3. Silber S. Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences. Z Kardiol 91 (2002) 443-457
4. Eisenberg M.J., and Konnyu K.J. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol 98 (2006) 375-382
5. Tung R., Kaul S., Diamond G.A., and Shah P.K. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med 144 (2006) 913-919
6. Kotani J., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
7. Nebeker J.R., Virmani R., Bennett C.L., Hoffman J.M., Samore M.H., Alvarez J., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
8. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
9. Feres F., Costa Jr. J.R., and Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 68 (2006) 83-88
10. Massberg S., Gawaz M., Gruner S., Schulte V., Konrad I., Zohlnhoefer D., et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 197 (2003) 41-49
11. Nieswandt B., and Watson S.P. Platelet-collagen interaction: is GPVI the central receptor?. Blood 102 (2003) 449-461
12. Massberg S., Konrad I., Bultmann A., Schulz S., Muench G., Peluso M., et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18 (2004) 397-399
13. Gawaz M., Konrad I., Hauser A.I., Sauer S., Li Z., Wester H.J., et al. Non-invasive imaging of glycoprotein VI binding to injured arterial lesions. Thromb Haemost 93 (2005) 910-913
14. Lincoff A.M., Topol E.J., and Ellis S.G. Local drug delivery for the prevention of restenosis. Fact, fancy and future. Circulation 90 (1994) 2070-2084
15. Popma J.J., Califf R.M., and Topol E.J. Clinical trials of restenosis after coronary angioplasty. Circulation 84 (1991) 1426-1436
16. Wilensky R.L., March K.L., Gradus-Pizlo I., Spaedy A.J., and Hathaway D.R. Methods and devices for local drug delivery in coronary and peripheral arteries. Trends Cardiovasc Med 3 (1993) 163-170
17. Herdeg C., Oberhoff M., Baumbach A., Blattner A., Axel D.I., Schröder S., et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 35 (2000) 1969-1976
18. Herdeg C., Oberhoff M., Baumbach A., Schroeder S., Leitritz M., Blattner A., et al. Effects of local all-trans-retinoic acid delivery on experimental atherosclerosis in the rabbit carotid artery. Cardiovasc Res 57 (2003) 544-553
19. Wolinsky H., and Thung S.N. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 15 (1990) 475-481
20. Lambert C.L., Leone J.E., and Rowland S.M. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis 4 (1993) 469-475
21. Herdeg C., Oberhoff M., Baumbach A., Blattner A., Küttner A., Schröder S., et al. Visualization and comparison of drug effects after local paclitaxel delivery with different catheter types. Basic Res Cardiol 94 (1999) 454-463
22. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
23. Bultmann A., Herdeg C., Li Z., Münch G., Baumgartner C., Langer H., et al. Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo. Thromb Haemost 95 (2006) 763-766
24. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
25. Rowinsky E.K., and Donehower R.C. Paclitaxel (Taxol). Review article. N Engl J Med 332 (1995) 1004-1014
26. Jordan M.A., Toso R.J., Thrower D., and Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90 (1993) 9552-9556
27. Axel D.I., Kunert W., Göggelmann C., Oberhoff M., Herdeg C., Küttner A., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
28. Herdeg C., Oberhoff M., Siegel-Axel D.I., Baumbach A., Blattner A., Küttner A., et al. Paclitaxel: Ein Chemotherapeutikum zur Restenoseprophylaxe? Experimentelle Untersuchungen in vitro und in vivo. Z Kardiol 89 (2000) 390-397
29. Dommke C., Haase K.K., Süselbeck T., Streitner I., Haghi D., Metz J., Borggrefe M., and Herdeg C. Local paclitaxel delivery after coronary stenting in an experimental animal model. Thromb Haemost 98 3 (2007) 674-680
30. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer- based, paclitaxel- eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
31. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 356 4 (2007) 325-328
32. Tanabe K., Serruys P.W., Degertekin M., Guagliumi G., Grube E., Chan C., et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 109 (2004) 196-200
33. Silber S. Cypher versus taxus: are there differences?. J Interv Cardiol 18 6 (2005) 441-446